에이치엘비는 끊임없는 열정과 노력으로 다양한 사업분야에서
미래의 변화를 주도하고 있습니다.
Apatinib in treatment of refractory gastric cancer
Author : Fudan University Shanghai Cancer Center, Shanghai Medical College, Department of Medical Oncology , Shanghai 200032 , China.
Source : NCBI
Antiangiogenesis therapy plays an important role in cancer treatment. Apatinib mesylate, a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has been recommended as third-line treatment for metastatic gastric cancer patients.
The current review summarizes the publications and conference reports relating to apatinib from preclinical and clinical research in gastric cancer. Apatinib showed good safety, tolerance and treatment efficacy in Phase I/II studies. In a Phase III study, apatinib prolonged the median overall survival of patients with chemotherapy-refractory metastatic gastric cancer by 55 days and the median progression-free survival by 25 days compared with placebo.
Apatinib is a new treatment option for advanced gastric cancer. Apatinib is expected to have a broader application when it has been evaluated worldwide. The key issues are to find biomarkers and overcome drug resistance.